Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

Newswire.ca - Press Release

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here

EPALINGES, Switzerland and PARIS, April 22, 2025 /CNW/ -- Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, Emercell SAS, has received Investigational Medicinal Product Dossier (IMPD) approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of OT-C001, an allogeneic natural killer (NK) cell therapy, in combination with an anti-CD20 monoclonal antibody, Rituximab.

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Most Popular News

Investor checking market data by SAI SU PAW KA via Shutterstock 1
Forget Nvidia and Broadcom. This Forgotten Retail Stock Is a Top Performer in 2025.
Image of Warren E_ Buffett by Photo Agency via Shutterstock 2
No ‘Intelligence or Emotional Stability’ Required: Warren Buffett Warns Short-Term Markets Are a ‘Voting Machine,’ But Eventually Reflect Reality
Double explosure with businesss charts and financial district of megapolis city by Golden Dayz via Shutterstock 3
Stocks Climb Before the Open on Micron Boost Ahead of U.S. Inflation Data
Doctor holding money by IherPhoto via iStock 4
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside
A Palantir sign displayed on an office building by Poetra_RH via Shutterstock 5
How Much You’d Have If You Bet $10,000 on Palantir Stock in January and 1 Key PLTR Catalyst to Watch in 2026
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot